MUC5AC and pancreatic intraductal papillary-mucinous neoplasm: The use of MUC5AC+ EV diagnosed inv/HG IPMN in 36% of cases that would have been otherwise missed by imaging alone, giving MUC5AC great potential as a biomarker for improved clinical decision-making in patients at high risk of PC lesions [81].